Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) Clinical research trials and Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Phase I Safety Study of anti-HIV Immune Serum Globulin (Human). Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) clinical trial. Test subjects typically obtain the finest healthcare available for their Phase I Safety Study of anti-HIV Immune Serum Globulin (Human) condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase I Safety Study of anti-HIV Immune Serum Globulin (Human)

Phase I Safety Study of anti-HIV Immune Serum Globulin (Human)



Phase I Safety Study of anti-HIV Immune Serum Globulin (Human)

For Condition: HIV Infections
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Proof of HIV infection. - Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3 months of AZT therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - HIV-induced neurological disease. - IgA negative. Concurrent Medication: Excluded: - Immunomodulating agents. - Steroids. - Interferons. Patients with the following are excluded: - Active substance abuse. - Use of immunomodulating drugs such as steroids or interferons. - HIV-induced neurological disease. - IgA negative. Required with a diagnosis of AIDS: - = or > 3 months of zidovudine (AZT) therapy. Active substance abuse.
Total Enrollment: 12

Location and Contact Information:

Univ of Minnesota
Minneapolis,  Minnesota,  55455
United States
 


Additional Information:
Study ID Numbers:  060A;  0001-008
Study Start Date: 
Record last reviewed: February 1990
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002036

Other Hiv Infections Studies:
1. Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

2. Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

3. A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART

4. Quality of Life in Children with HIV Infection

5. The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

Related Studies:

Other HIV Infections Clinical Trials
Other Minnesota Clinical Trials
Other Minneapolis Clinical Trials

Phase I Safety Study of anti-HIV Immune Serum Globulin (Human)
Modify your Search

  Other HIV Infections Clinical Trials
  Other Minnesota Clinical Trials
  Other Minneapolis Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103